



Published in final edited form as:

Endocrinol Metab Clin North Am. 2017 December ; 46(4): 1009–1038. doi:10.1016/j.ecl.2017.07.007.

Vitamin D Receptor Signaling and Cancer

Moray J. Campbell, MS, PhD^{a,*}, Donald L. Trump, MD^b

^aDivision of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, 536 Parks Hall, Columbus, OH 43210, USA;

^bDepartment of Medicine, Inova Schar Cancer Institute, Virginia Commonwealth University, 3221 Gallows Road, Fairfax, VA 22031, USA

Keywords

Vitamin D; Chemoprevention; Chemotherapy; TCGA; Genomics

A PRIMER ON VITAMIN D BIOLOGY AND MEDICINE

The primary biological action of the secosteroid hormone vitamin D ($1,25(\text{OH})_2\text{D}_3$) is to bind to the vitamin D receptor (NR1H1/VDR) and to regulate serum calcium levels. As a downstream consequence, the actions of the receptor control bone formation and maintenance. The first clinical manifestation of insufficient VDR endocrine signaling, rickets, was discovered by Daniel Whistler in the Netherlands in the 17th century; 300 years later, the VDR gene was cloned by Bert O'Malley and coworkers.¹ Between these dates, research into vitamin D was at the forefront of areas of public health, chemistry and biochemistry including the light catalyzed synthesis of vitamin D₃ by Adolf Windaus. For this work, he received the Nobel Prize in Chemistry (1928). Work in the 1960s and 1970s led to analyses of vitamin D endocrine metabolism and led to remarkable strides describing biochemical synthesis of $1,25(\text{OH})_2\text{D}_3$ and the diverse biology in which VDR participates.

The precursor of $1,25(\text{OH})_2\text{D}_3$, cholecalciferol or vitamin D₃, is produced in the skin and converted in the liver to 25-hydroxyvitamin D₃, ($25(\text{OH})\text{D}_3$); circulating levels of $25(\text{OH})\text{D}_3$ serve as a useful index of vitamin D total body stores. A further hydroxylation occurs in the principally in the kidney at the carbon 1 position by 25-hydroxyvitamin D-1 α -hydroxylase (encoded by *CYP27B1*) to produce the biologically active hormone, $1,25(\text{OH})_2\text{D}_3$. A second mitochondrial cytochrome P450 enzyme, the 24-hydroxylase (encoded by *CYP24A1*), can use both $25(\text{OH})\text{D}$ and $1,25(\text{OH})_2\text{D}_3$ as substrates, and is the first step in the inactivation pathway for these metabolites. Because of the direct role $1,25(\text{OH})_2\text{D}_3$ plays in control of serum calcium levels, elevated levels of $1,25(\text{OH})_2\text{D}_3$ block its synthesis and induce inactivation and accelerate catabolism² via induction of CYP24A1, in a classical negative feedback loop.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Corresponding author. Campbell.1933@osu.edu.

In parallel to these VDR-centered discoveries a greater awareness emerged of the 48 members of the nuclear hormone receptor (NR) superfamily, of which the VDR is a member. As a result, the VDR and other NRs represent some of the most well-studied human transcription factors and have yielded significant insight into the mechanisms of transcriptional control.

It is worth stressing the fundamental importance of the precise monitoring and regulation of serum calcium levels to human health; hence, the endocrine role of the VDR in the regulation of calcium homeostasis is critical. The levels of vitamin D depend on cutaneous synthesis initiated by solar radiation and on dietary intake; a decrease of either one or both sources leads to insufficiency. The contribution from the ultraviolet light (UV)-initiated cutaneous conversion of 7-dehydrocholesterol to vitamin D₃ is the greater, contributing more than 90% toward final 1,25(OH)₂D₃ synthesis in a vitamin D-sufficient individual.

The importance of the relationships between solar exposure and the ability to capture UV-mediated energy is underscored by the inverse correlation between human skin pigmentation and latitude and associated 25(OH)D levels. That is, skin pigmentation was lost as humans migrated out of Africa to adjust to life with reduced solar UV exposure. As a result, individual capacity to generate vitamin D₃ in response to solar UV exposure is intimately associated with forebear environmental adaptation. The correct and sufficient level of solar exposure and serum vitamin D₃ are matters of considerable debate, and an Institute of Medicine report³ in 2010 recommended daily vitamin D₃ intake at the levels of 600 IU/d for most groups in the population (800 IU/d for those >70 years of age). However, this recommendation is not without controversy; parallel reassessment of the vitamin D impact on the prevention of osteoporosis has suggested that the correct level may be as high as 2 to 3000 IU/d, which may reflect more accurately ancestral serum levels.⁴ Another challenge is determining how a given intake relates to serum levels among individuals^{5,6} and what are the appropriate biochemical readouts for measuring systemic response.

However, given that there has been a concerted research focus on VDR signaling, there now exists a fairly sophisticated appreciation of this process, and it has been extensively reviewed.⁷⁻¹³

WHY CONSIDER TREATING CANCER WITH VITAMIN D COMPOUNDS?

The first report that VDR actions could control cancer cell growth were discovered partly through serendipity, and partly through logical extension of other studies. Reports in the 1970s identified purified cell fractions that bound 1,25(OH)₂D₃ with high affinity,¹⁴ and encouraged investigators to begin to consider what were the molecular actions of the VDR in the classic tissues involved in calcium homeostasis, for example, skin, bone, intestine, and kidney.¹⁵ In 1981, Kay Colston and coworkers¹⁶ were first to demonstrate that 1 α ,25(OH)₂D₃ at nanomolar concentrations inhibited human melanoma cell proliferation in vitro. That the workers used a cancer cell model was serendipitous; cancer cell models are more readily available to study in cell culture experiments than nonmalignant counterparts, and in this case¹⁶ the cells chosen were available in an adjacent laboratory.

In parallel, it was also known that retinoids, which are also small lipophilic molecules that target NRs, could drive cell differentiation, for example, in HL60 leukemia cells lines cells.¹⁷ In turn these studies led to the pharmacologic exploitation of all-*trans* retinoic acid in acute promyelocytic leukemia (APL). The molecular cause of APL are translocations of the RAR γ receptor forming chimeric proteins such as PML-RAR γ . These chimeric proteins disrupt the control of differentiation and give rise to APL.^{18–20} Pharmacologic doses of all-*trans* retinoic acid are able to trigger differentiation and, therefore, this therapy in APL is a dramatic example of targeted cancer therapies; in addition, these findings contributed significantly to the rise of the concept of differentiation therapy.^{21–29} All-*trans* retinoic acid remains the mainstay of therapy for APL^{30,31} and this is a major catalyst for studying RARs across cancers.^{29,32,33} As a result, workers began to consider exploiting the antiproliferative actions of 1,25(OH)₂D₃ as a differentiation therapy in cancers. In the first instance, the ability of 1,25(OH)₂D₃ to induce differentiation in cultured mouse and human myeloid leukemia cells was examined.^{34,35} From the early 1980s onwards the antiproliferative effects of 1,25(OH)₂D₃ have been explored in a wide variety of cancer cell lines, which include all major solid tumors and leukemia.^{36–43}

WHAT HAS BEEN LEARNED FROM PRECLINICAL STUDIES?

One of the most highly cited papers in the last 20 years of cancer research is the *Hallmarks of Cancer* paper by Douglas Hanahan and Robert Weinberg.⁴⁴ This landmark paper defined 6 stages necessary for cancer to develop and be sustained. Although this work has been expanded to include additional steps, this original thesis provides a highly significant backdrop against which to examine anticancer VDR functions.

Insensitivity to Antigrowth Signals and Evasion of Apoptosis

Cancer cells sustain their own proliferative signals and silence cues for programmed cell death. Signaling via 1,25(OH)₂D₃ drives antiproliferative events, and counters the insensitivity to antigrowth signals and the evasion of apoptosis in cancer cells. Multiple investigators have examined the mechanistic basis for cell sensitivity to VDR antiproliferative responses. For example, early studies focused on understanding antiproliferative pathways, be they mediating cell cycle arrest^{37,45–47} or programmed cell death.^{48–50} However, other studies supported a role for 1,25(OH)₂D₃ to block or impede programmed cell death.^{51,52} Historically, hematologic malignancies combined an ease of interrogation with robust classification of cellular differentiation capacity that were envied by investigators of solid tumors. It is, therefore, no coincidence that these cell systems led to the identification of VDR control of genes that control cell cycle progression, including p21^(waf1/cip1) and p27^(kip1), as well as the direct binding sites on the gene *CDKN1A* (encodes p21^(waf1/cip1)).^{53,54} The regulation of p27^(kip1) seems to be mechanistically enigmatic and exemplifies the broad effects of VDR signaling in that both transcriptional and translational regulation, such as enhanced mRNA translation, and attenuating degradative mechanisms are described?^{55–58}

The upregulation of p21^(waf1/cip1) and p27^(kip1) principally mediate G₁ cell cycle arrest, but 1 α ,25(OH)₂D₃ has been shown to mediate a G₂/M cell cycle arrest in a number of cancer

cell lines via direct induction of GADD45 α .^{59–61} Concomitant with these events is a downregulation of cyclins such as cyclin A, a decrease in kinase activities associated with activated complexes, and ultimately the dephosphorylation of the retinoblastoma protein and sequestration of E2F family members in a repressive complex.⁶² Concomitant with changes in the cell cycle, 1,25(OH)₂D₃ induces differentiation, most clearly evident in myeloid cell lines, but also supported by other cell types and most likely reflects the intimate links that exist between the regulation of the G₁ transition and the induction of cellular differentiation.^{63–72}

Programmed cell death has been reported in breast cancer models and leukemia models,^{73–76} with evidence that the levels of BCL-2 family of proteins are tightly regulated.⁷⁷

Treatment with 1 α ,25(OH)₂D₃ upregulates vitamin D upregulated protein 1, which binds to the disulfide reducing protein thioredoxin and inhibits its ability to neutralize reactive oxygen species, which in turn can lead to stress-induced apoptosis.^{78–80}

Tissue Invasion and Metastasis

VDR signaling enhances adhesion and suppresses the invasive capacity of cells; many of these effects are associated with a more differentiated phenotype. In an elegant series of studies, Munoz and coworkers have dissected the relationships between VDR signaling and invasion in colon cancer cell lines and primary tumors.^{81–86} These workers established the delicate interplay between VDR, E-cadherin, and the Wnt signaling pathway in cell lines and clinical samples. Others have examined adhesion protein expression in other cancer models, suggesting that these mechanisms may be generalizable beyond colon cancer cells.^{88,87–89}

Limitless Replicative Potential

An essential component of cancer is the ability to replicate without limits that often requires silencing of mechanisms of genomic surveillance. The VDR seems to play roles in maintaining genomic integrity and facilitating DNA repair. There is close cooperation between VDR actions and the p53 tumor suppressor pathway. Correlative data suggest that, generally, cells that respond to 1,25(OH)₂D₃ most profoundly have wild-type p53, and at the molecular level several target genes are shared by both signaling pathways, such as *CDKN1A* and *GADD45A*.^{53,54,59,90–95} Notably in the skin, VDR signaling is combined with surveillance of genomic damage to regulate mitosis negatively.^{96,97} In other epithelial tissues, close cooperation between VDR regulates *BRCA1* mRNA and protein via transcriptional activation, again supporting a role in genomic surveillance.^{98–100}

IDENTIFYING VITAMIN D RECEPTOR–MEDIATED TRANSCRIPTOMES

To identify critical target genes that mediate these actions, comprehensive genome-wide transcriptomic screens have revealed broad consensus on certain targets, but have also highlighted variability.^{36,60,101,102} There is a significant history of VDR-centric transcriptomic studies that support the cell phenotypes observed.^{36,60,61,101–111} For example, the study of isogenic cell pairs with differing sensitivities to 1,25(OH)₂D₃ signaling has identified networks that mediate antiproliferative sensitivity. In this manner, a significant

role of cross-talk between VDR and transforming growth factor (TGF)- β signaling has been revealed.^{112,113} In addition, similar studies have shown that VDR transcriptional targets can distinguish leukemia aggressiveness.¹¹⁴ The list of gene targets that is common across cell models seems to be short; the most clearly shared target is CYP24A1. Beyond that, commonly enriched gene networks often focus on cell cycle control and signal transduction. However, substantial variations in experimental design (eg, dose, exposure time, and use of 1,25(OH)₂D₃ or an analog) limit strict comparisons. Thus, although a formal metaanalysis to reveal common themes has not been applied,^{115,116} it seems clear that there is little overlap between the transcriptomic studies. It is also noteworthy that datasets have been developed that are aimed at noncoding RNA species.^{117,118} Therefore, the diversity of the VDR regulated transcriptome is likely to increase.

More recently, these transcriptomic studies have been complemented by VDR ChIP-Seq studies in which the VDR genomic binding patterns have been captured. VDR ChIP-seq studies have been performed in several human cell types,^{119–123} in the presence and/or absence of ligand, and revealed the impact of ligand binding on VDR genomic targeting. Arguably, VDR ChIP-seq studies are more important than transcriptomic studies because they reveal direct VDR genomic interactions, whereas transcriptomic analyses inevitably include direct and indirect VDR-mediated effects. Each VDR ChIP-Seq analysis revealed approximately 2000 to 6000 genomic loci normally distributed around transcription start sites, reflecting the binomial distributions found for other transcription factors,^{123,124} but many loci are found at considerable distance from the transcription start sites. Another important finding from these studies is that the dual hexameric DNA motif spaced by 3 bp, a so-called DR3 motif,^{125,126} is found in the majority but not all of the most prominent genomic VDR binding sites. Other binding motifs have also been suggested, for example, an inverted palindrome spaced by 9 bp, a so-called IP-9.^{127,128} The application of ChIP-Seq approaches to NRs in general has revealed greater binding site diversity than previously expected; in addition the importance of flanking regions for cofactors to be biologically important to determine function.¹²⁹ These aspects of transcriptional regulation are described in greater depth in J. Wesley Pike and Sylvia Christakos' article, "Biology and Mechanisms of Action of the Vitamin D Hormone," in this issue.

The precise frequency of DR3 type elements in part remains ambiguous, because it depends on a number of variables that include the depth of the sequence read, the precise discovery motif algorithm applied, and the statistical thresholds used. Regardless of the actual percentage of VDR binding sites that contain DR3 motifs, it is clear that the VDR binds in significant levels to genomic regions that do not contain a canonical DR3. This may be explained by the VDR interacting with the genome in both direct (VDR–DNA) and indirect (VDR–protein–DNA) modes (reviewed in reference⁸).

There is a compelling case to be made for the reanalysis of the VDR ChIP-Seq data, from genomic alignment to differential peak calling. The rationale for reanalyses is two-part. Analyses of ChIP-Seq is not trivial in terms of statistical assumptions, and the existing studies have all been analyzed in a different manner. Therefore, there is the possibility that thresholds and cutoffs differ between studies. Second, the methodologies for ChIP-Seq

processing are an area of active development and advancement, and the most recent approaches display a number of benefits over earlier analytical workflows.¹³⁰

IN VIVO VITAMIN D RECEPTOR ANTICANCER ACTIONS

Given this wealth of understanding of the broad anticancer actions of the VDR, and the aim to exploit this understanding in cancer settings, the use of rodent models is a major intermediary step before clinical exploitation of VDR signaling in either chemoprevention or chemotherapy settings.

A clear difficulty in investigating the efficacy of targeting VDR with either 1,25(OH)₂D₃ or analogues that have more attractive pharmacologic properties^{33,126,131–140} is that mice are not humans. Their spectra of age-associated malignancies are different from humans and other key metabolic differences exist. Recapitulating these lifetime effects are further compounded by the need to establish the window in which chemoprevention effects may play a role in either tumor initiation or progression.

Notwithstanding these caveats, the *Vdr*^{-/-} animals are extremely useful tools to elucidate more clearly the role for the VDR to act in a cancer preventive manner.^{2,141,142} A series of animals have been generated in which the VDR-ablated background has been crossed into animals with tumor disposition phenotypes. In the first instance, there is evidence that deleting or reducing VDR levels alters the morphology in the colon^{143,144} and breast.¹⁴⁵ Furthermore, crossing the *Vdr*-deficient and heterozygote mice with mouse mammary tumor virus-*neu* transgenic mice has generated animals that show a degree of *Vdr* haplosufficiency.¹⁴⁵ The mammary tumor burden in the crossed mice is reduced with the presence of one wild-type *Vdr* allele and further with 2 wild-type *Vdr* alleles. Alternatively, the *Vdr*^{-/-} animals demonstrate greater susceptibility to carcinogen challenge. For example, challenging *Vdr*^{-/-} mice with DMBA induced more preneoplastic lesions in the mammary glands than in wild-type mice.¹⁴⁶

Previously, other workers have established that deletion of the Adenomatous polyposis coli (*Apc*) gene in a mouse can faithfully recapitulate human colon cancer. In turn, these mice have been exploited to examine the impact of *Vdr* deletion on the progression of colon cancer¹⁴⁷; similar studies support an antitumorogenic role for the VDR in the skin.¹⁴⁸ Numerous studies have examined the ability of dietary or pharmacologic addition of vitamin D compounds to either prevent tumor formation or inhibit the growth of xenograft tumors.^{82,149–159}

One area of investigation is the impact of experimental dietary variations and their impact on tumor predisposition. Long-term studies of mice fed with a Western-style diet (eg, high fat and phosphate and low vitamin D and calcium content) have been exploited to examine the impact of vitamin D on colon cancer proliferation.¹⁶⁰ Similarly, vitamin D and calcium dietary interventions can modulate colon crypt hyperplasia¹⁶¹ and provide a rationale for how diet, inflammation, and premalignant cells could all interact and modulate cancer progression.^{143,162–165}

HUMAN EPIDEMIOLOGIC FINDINGS AND CLINICAL TRIALS

Epidemiologic studies by Cedric Garland and coworkers were the first to investigate relationships between intensity of sunlight exposure and cancer incidence and revealed an inverse correlation with risk of colon cancer, and subsequently extended these findings to implicate a relationship with other cancers.^{166–170} For example, levels of 25OH-D, the major circulating metabolite of vitamin D, are significantly lower in breast cancer patients than in age-matched controls.^{171–173} However, these relationships are clearly complex and reflect lifetime exposures, and indeed controlling for lifestyle factors can significantly impact the strength of the relationships.¹⁷⁴ Although these are all association studies, and therefore function cannot be readily inferred, there are some suggestive findings that low serum levels of 25OH-D are an unfavorable prognostic indicator^{175–178} or may trigger worse chemotherapy responses.¹⁷⁹ In other cancers, prostate for example, the relationships are more equivocal, with some positive findings,^{180,181} although more generally the results are not able to support a cancer-preventative impact of vitamin D levels.^{182–185} To address these ambiguities, investigators are now in the first stages of randomized supplementation trials,¹⁸⁶ one of which, VITAL (VITamin D and omega-3 Trial), has now accrued 25,000 people and is examining the impact of supplementing vitamin D and omega 3 fatty acid on a range of pathologies, principally cancer and heart disease incidence¹⁸⁷

Collectively, these preclinical studies and aspects of the epidemiologic findings encouraged academic and pharmaceutical partnerships in the design of vitamin D analogues that may have an optimal balance of in vivo properties to be used as a chemoprevention or chemotherapy agent. Optimizing vitamin D compounds for in vivo anticancer efficacy is aimed at ensuring a favorable balance between calcium mobilizing actions, which result in hypercalcemia, and enhancing the anticancer actions of targeting the VDR. Several medicinal chemistry groups undertook this goal, led in many ways by the group of Milan Uskokovic at Hoffman la Roche,^{64,188–200} alongside Lisa Binderup at Leo Pharmaceuticals,^{201–204} as well as other groups in academic settings, including Gary Posner.^{205–208} Together, these and other investigators have synthesized a blizzard of vitamin D analogues that have many promising properties, being resistant to metabolism and yet have tolerable impact on serum calcium levels.

Several of these analogues have served as the lead compounds in the search for disease settings where the anticancer actions of vitamin D compounds can be exploited. For example, phase I trials have been undertaken in a range of advanced cancers^{209,210} and led to more targeted phase II trials in pancreatic,²¹¹ liver,²¹² prostate,^{213–216} and breast cancers.^{186,217} In all cases, the regimens were well-tolerated but clinical responses were at times modest. However, this in part may reflect that the doses chosen were too conservative and the correct endpoints for these trials would be measuring cellular differentiation (or reduced proliferation or enhanced apoptosis), and this is not readily undertaken in the context of clinical trials.

These challenges are illustrated by considering prostate cancer in more detail. A number of investigators have considered the option of treating men with localized disease before surgery and then studying the prostate tumor after surgery for characterization of known

VDR target genes. In a trial of nearly 40 patients with localized prostate cancer, Beer and colleagues²¹⁸ administered either 1,25(OH)₂D₃ or placebo for 4 weeks before radical prostatectomy. Expression changes in the VDR or known candidate VDR target genes of markers of cell proliferation were examined. Interestingly VDR was downregulated in the treatment group, whereas the other genes chosen (eg, *TGFBR2*) were unchanged. Others replicated this approach but with doxercalciferol and revealed significant modulation of *TGFBR2*. Interestingly, microarray studies of 1,25(OH)₂D₃ sensitivity in isogenic breast cancer cell lines established that *TGFBR2* was a critical mediator and marker of sensitivity toward 1,25(OH)₂D₃.¹¹² Other investigators have examined the question of efficacy by escalating dose to assess how well higher levels of 1,25(OH)₂D₃ can be tolerated.²¹⁹ Together these studies suggest that 1,25(OH)₂D₃ can be given to prostate cancer patients at quite high doses and changes in expression of VDR-dependent genes can be observed.

This finding has also led others to consider how chemotherapy with 1,25(OH)₂D₃ could be potentiated by combinations with other cytotoxic agents for added clinical benefit. Such combination studies are intrinsically challenging; in the vitamin D arena, Novoclea undertook such an approach in their development of DN-101 (a new formulation of 1,25(OH)₂D₃) as a cancer therapy in combination with docetaxel for men with advanced prostate cancer that had failed hormonal therapy, so-called castration resistant prostate cancer. Based on numerous preclinical studies and a single institution clinical study, Novoclea conducted a randomized phase III study (ASCENT I [AIPC Study of Calcitriol ENhancing Taxotere]) to determine whether the prostate-specific antigen response rate (defined as a >50% decline in prostate-specific antigen for >1 month) was different for the standard therapy for castration resistant prostate cancer at the time (docetaxel 36 mg/m² weekly intravenously for 4 weeks every 6 weeks) compared with the same dose and schedule of docetaxel plus DN-101, 45 mg weekly.²²⁰ Although this study did not meet the prostate-specific antigen response criteria, it did alter the overall survival and therefore justified a large randomized trial to assess survival. This new trial (ASCENT II) was halted before full recruitment because survival in the DN-101 arm was reduced compared with standard of care. However, the ASCENT II trial design was seriously flawed: the chemotherapy in each arm was not equal in efficacy. The design of the trial was docetaxel A + DN-101 versus docetaxel B + placebo. Substantial data existed at the time that the trial was initiated that docetaxel A was clearly inferior to docetaxel B in terms of survival in men with castration resistant prostate cancer. Therefore, the trial was actually designed to ask the question, can DN-101 overcome the inferiority of docetaxel regimen A.

A more fundamental flaw of both trials was that the dose of 1,25(OH)₂D₃ chosen was neither the biologically optimal nor the maximum tolerated dose. Other studies have clearly shown that a 2 to 3 times higher doses of calcitriol can be given safely to such patients. However, the result of ASCENT II has been interpreted as “calcitriol does not potentiate docetaxel (and hence any chemotherapy) in a large clinical trial.” This is a conclusion based on no adequate data. As a result, the application of vitamin D formulations have probably been left in a challenging development point.²²¹

Given these tantalizing preclinical and epidemiologic findings, the question then is why have the clinical trials not been successful? It is clear that clinical exploitation of any drug is hard,

and there is a very high attrition rate of drugs passing from preclinical development to clinical implementation.²²² There are many therapies that struggle to balance preclinical promise with clinical realities, and the clinical development pipeline is often challenged by ensuring optimal clinical trial design, as illustrated by PARP inhibitors and antiangiogenesis therapies^{223–227} that, although approved by the US Food and Drug Administration, have required further reanalyses to define optimal efficacy.^{228,229} Therefore, it is possible that vitamin D–centered chemotherapies will fall to a similar fate. It may well be that, to date, an incomplete understanding of what are the desirable anticancer actions and inappropriate clinical trial design have impeded clinical success with vitamin D compounds.

CELLULAR MECHANISMS OF RESISTANCE

A major focus emerged on dissecting how cancer cells vary in their response to 1,25(OH)₂D₃. One initial focus was on genetic variation in the 3' and 5' regions of the VDR gene itself.^{230–233} For example, a start codon polymorphism in exon II at the 5' end of the gene, determined using the *fok*-I restriction enzyme, result in a truncated protein.²³⁴ These findings were initially suggestive of a functional relationship between VDR gene genetic variation and cancer risk, but in larger studies these associations seem to be equivocal, or more nuanced.^{235–242} Indeed, this is also reflected by the fact that the National Human Genome Research Institute genome-wide association studies (GWAS) catalog does not list any genome-wide significant genetic variation that is annotated to the VDR and related to cancer phenotypes; rather the genetic variation of the VDR seems to associate with immune, diabetic, and reproduction phenotypes.^{243–245}

Also at the genetic level, various investigators have considered how cell responsiveness to 1,25(OH)₂D₃ may be determined by the expression of the activating (CYP27B1) and metabolizing (CYP24A1) enzymes. For example, comparative genome hybridization studies found that *CYP24A1* is amplified in human breast cancer in relation to paired normal tissue.^{246,247} Others have revealed reduced *CYP27B1* mRNA and protein levels in a wide variety of cancer cell lines and primary tumors.^{248–254} Together these findings suggest that cancer cell sensitivity toward 1,25(OH)₂D₃ may primarily depend on autocrine metabolism in target cells rather than the endocrine synthesis and uptake in target cells. This raises the possibility that local control of these enzymes could be exploited in targeted VDR-centric therapies.

Finally, others have considered how epigenetic mechanisms may disrupt VDR signaling. Evidence for this approach arises from the observation that 1,25(OH)₂D₃-reclacitrant cells still often respond transcriptionally, but lack transcriptional responsiveness to antiproliferative target genes such as *CDKN1A*, but sustain or even enhance induction of *CYP24A1* gene.^{61,100,112,118,255} These data suggest that the VDR transcriptome is skewed in cancer cells to disfavor antiproliferative target genes, and that lack of functional VDR alone cannot explain resistance. The interactions of transcriptional corepressors such as NCOR1 and NCOR2/SMRT have been examined to investigate this possibility.^{61,256–261} In turn, altered VDR–corepressor interactions may form a molecular lesion that could be targeted by cotreatment of 1,25(OH)₂D₃ plus the HDAC inhibitors.^{262–267}

LESSONS FOR BIG DATA TO OPTIMIZE VITAMIN D RECEPTOR-CENTERED THERAPIES

Biology is very clearly in the genomic era, in which the sum total of genes, transcripts, proteins and metabolites in cells are captured and analyzed. Arguably, the achievements of the Human Genome Project²⁶⁸ served as a major catalyst for this approach, and other research consortia have applied similar technologies and approaches to tackle other fundamental challenges in biology. Powerful examples are illustrated by Encyclopedia of DNA coding elements (ENCODE),^{269,270} RoadMap Epigenome,²⁷¹ Functional and Taxonomic Analysis of Metagenomes,²⁷² International Human Epigenome Consortium,^{273,274} the Cancer Genome Atlas (TCGA),²⁷⁵ and the Genotype-Tissue Expression (GTEx) project.²⁷⁶ The volume of data generated by these projects is unprecedented and truly transformative in terms of the questions that can be addressed, the manner in which they are tackled, and the how the findings are interpreted and widely translated.

Bioinformatic analyses are central to both the generation of these complex datasets and their investigation. Unbiased bioinformatics analyses can reveal organizational insight that is neither obvious nor intuitive. Unbiased and agnostic analyses are achieved by applying algorithmic approaches that depend on discrete mathematics and information theory, combined with graph theory, data mining, and computer science generally, with a central role for the statistical sciences. In this manner, bioinformatic approaches offer the promise to reveal underlying mechanisms of biology in health and disease.

For example, -omic technologies can be applied to capture genomic structural variants and mutations, gene and protein expression patterns, protein posttranslational modifications, and metabolites across cell states. Bioinformatics analyses is applied to all steps from data capture, to data processing (eg, filtering and normalization), to establishing reproducible changes between states A and B, and to more complex integrative analyses from combining different -omic datasets. The statistical sciences are central to all these steps. The ultimate goal from these workflows is to identify network changes between states, and finally to identify nodes that exert control. Such nodes would then form attractive targets for interventionist wet laboratory-based experiments.

Several points are worth stressing from this theoretic workflow. First, study design and phenotype definition are critical. Second, all analyses include a denominator (eg, the genome, the detectable transcriptome, etc) so that any change is considered against the appropriate backdrop of all events occurring in the cell. Third, all data processing includes normalization across samples, including replicates and states, and subsequent filtering to remove the large component of the signal that is unchanging to, therefore, control the penalties of false discovery. Finally, the integrative steps have very high potential for creativity and novelty. That is, as the volume of publicly available data grows, the statistical approaches and types of data integration that can occur are varied and represent where many of the key biological questions of the future will be framed.

The mechanics of VDR signaling and disruption in cancer can, therefore, be analyzed in the paradigm of mining and analyzing large biological datasets. Therefore, there are several

bioinformatics approaches that are applicable to the VDR. In the first instance, applying the genome as the denominator allows the question to be addressed of where VDR biology is significant. For example, in what cancer does a significant role for the VDR emerge when considering all genetic variations or gene expression?

At the simplest, GTEx project²⁷⁷ and the TCGA data can be investigated to identify in which normal tissue is the VDR most highly expressed, or in what cancer is it most commonly altered. The GTEx data reveal that the VDR is most abundant in tissues of the colon and small intestine, and least abundant in basal ganglia and brain tissues. The TCGA data reveal that the VDR is most commonly altered by deletion in 2 cohorts of adenoid cystic carcinoma of the breast.^{278,279} Interestingly, the GTEx data clearly reflect the focus at the preclinical and epidemiologic level of investigated VDR in colon cancer. However, no studies to date have examined VDR in the context of adenoid cystic carcinoma of breast cancer.

The TCGA^{280,281} data are derived from more than 33 different cancer types that were collected from approximately 11,000 patients. The analyses of these data have been the subject of more than 350 papers to date and it is striking that none of these papers identified a genome-wide significant role for disruption or association of the VDR with tumor phenotypes. By comparison, more than 100 TCGA papers report a significant relationship with TP53.

Often, biological signals are extremely contextual. Analyses of myeloid²⁸² and megakaryocyte²⁸³ cells illustrate that there is a significant role for the VDR to act in distinct transcriptional units that control specific points of cell differentiation. These findings reveal the intricate mechanistic basis to some of the earliest cancer studies on VDR signaling in leukemia,^{284,285} which revealed that exogenous vitamin D compounds can trigger cell differentiation. Therefore, reflecting on the role VDR seems to be playing in myeloid systems, it is worth stressing the apparent importance of VDR in immune phenotypes. That is, GWAS identify significant roles for VDR genetic variation in immune phenotypes.^{244,286,287}

Perhaps reflecting the reproduction-related functions of the VDR in murine systems,²⁸⁸ the *Vdr*^{-/-} mice display a mammary gland phenotype, and this genotype can modulate cancer incidence in murine cancer models.^{145,289,290} However, transcriptional and epigenomic control of breast epithelial systems in human cells does not reveal a genome-wide significant role for the VDR,²⁹¹ and the major breast cancer papers from TCGA have not identified a genome-wide significant role for the VDR to act as a cancer driver.²⁹²⁻²⁹⁵

Putting these findings together from leukemia and common cancers suggests that the VDR itself does not act as a direct cancer driver, either through loss or gain of function. This finding may limit the likelihood of therapeutic exploitation in the cancer context.

Other approaches can be applied to leverage public data by changing the denominator. It is possible to address questions centered around the VDR and related genes, and thereby limit the penalties of false discovery. For example, previously we analyzed 13 transcription factor families implicated in cancer, including the NR superfamily, across 3000 tumors from 6

different tumor types.^{296–300} Bootstrapping approaches³⁰¹ established that, across cancers, only the NR family was significantly downregulated, but was neither significantly mutated nor altered by copy number variation.³⁰² Within the NRs, we found that several NRs were uniquely suppressed in only one tumor site, including *VDR* in the colon cancer (COAD) cohort; this finding may reflect the strong expression of *VDR* in the normal colon. *VDR* downregulation was not found to be driven by copy number variation or mutation and thus epigenetic mechanisms may be primarily responsible for altered expression.^{301,302} There is a very well-established literature supporting links between corrupted *VDR* signaling and colon cancer.^{85,147,303–308} Our pan-cancer analyses add to these findings, suggesting that loss of *VDR*-induced growth restraint may be more apparent in colon cancer than in other cancers where alterations are not apparent.

The *VDR* ChIP-seq data also lend themselves to be combined with other types of publicly available data to ask further questions concerning *VDR* function. For example, an attractive integration approach is to examine how significant genetic variation in transcription factor binding site can relate to phenotypes and disease susceptibility. Testing the possibility that genetic variation impacts transcription factor function underpins trait differences and disease phenotypes is analytically challenging, given the size of the datasets and the potential for false discovery. Various groups have addressed this challenge; notably, both the ENCODE and Roadmap Epigenome consortia leveraged the remarkable volume of ChIP-seq data they generated and merged the binding sites with GWAS data to reveal and rank sites where single nucleotide polymorphisms (SNPs) seem to have a significant impact on the activity of multiple transcription factors.^{124,271,309}

However, given that *VDR* has not been considered in any of these consortia, we have recently integrated *VDR* ChIP-Seq^{119–123} with National Human Genome Research Institute GWAS SNPs, and SNPs in linkage disequilibrium, to provide novel insight into the interaction between disease- and phenotype-associated SNPs and *VDR* binding. From these analyses, we applied transcription factor motif searching and exploited other ChIP-Seq data to identify significant interactions between the *VDR* and other transcription factors and disease traits. In this manner, we identified genetic variation that was significant at the genome-wide level enriched in *VDR* binding sites that were shared with nuclear factor- κ B binding regions related to immune phenotypes, including self-reported allergy.³¹⁰ However, none of the GWAS SNPs identified in *VDR* binding sites were neither in a DR3 type motif, again underscoring the diversity of *VDR* binding sites, nor related to cancer phenotypes.

However, there does seem to be a significant relationship between *VDR* and colon cancer, given that the *VDR* is highly expressed in the normal colon, associated with the control of local immunity,^{82,308,311–315} and that, of all the NRs, the *VDR* is commonly and significantly downregulated in colon cancer. To test this possibility, we leveraged *VDR* ChIP-Seq data derived in LS180 colon cancer cells¹²¹ with the expression of *VDR* target genes in the TCGA–COAD cohort.²⁹⁸ Clustering the tumors by expression patterns then allowed testing the relationships between expression of *VDR* target genes and clinical outcome. Expression of *VDR* target genes were either significantly repressed or activated in the COAD cohort, suggesting that *VDR* functions in both activating and repressing complexes at the basal (or physiologically activated) state.³¹⁶ For instance, *LGALS4* is a

VDR target gene that is specific to colonic cells and is downregulated in colon cancer, acting as a tumor suppressor,^{303,317,318} and *LGALS4* quartile expression patterns significantly associated with disease-free survival in specific patient subgroups.

A further opportunity available for meaningful data integration of ChIP-Seq studies is in the judicious choice of the cell line of study. For example, there are 3 tier 1 cell lines in the ENCODE project including K562 cells, which has approximately 600 publicly available genome-wide datasets. Therefore, there is an exciting opportunity once VDR ChIP-Seq is undertaken in one of these models in terms of integrative analyses³¹⁹ that could leverage ENCODE or RoadMap Epigenome data.

FUTURE CONSIDERATIONS AND SUMMARY

Enthusiasm remains for exploiting vitamin D signaling in cancer systems. This partly reflects that the biology is now very well-understood, that the toxicities associated with vitamin D compounds are easily monitored and managed and that in an era of high dimensional biological data it is possible to measure and dissect the actions of VDR signaling in very great detail. It seems likely that efforts will continue to exploit vitamin D compounds in the clinical setting, and it may well be that by exploiting tools to very accurately measure tumor type and burden will allow vitamin D-centered therapies to be applied with great precision. It seems likely that among the actions of VDR, the immunomodulatory capacity may ultimately be the ones that are most advantageous in cancer therapies.

ACKNOWLEDGMENTS

M.J. Campbell acknowledges support in part from the Prostate program of the Department of Defense Congressionally Directed Medical Research Programs [W81XWH-14-1-0608, W81XWH-11-2-0033]. D.L. Trump acknowledges the support of the Inova Schar Cancer Institute and the generosity of the Schar Family.

REFERENCES

1. Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. *Proc Natl Acad Sci U S A* 1988;85: 3294–8. [PubMed: 2835767]
2. Takeyama K, Kitanaka S, Sato T, et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. *Science* 1997;277:1827–30. [PubMed: 9295274]
3. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. *J Clin Endocrinol Metab* 2011;96:53–8. [PubMed: 21118827]
4. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. *Osteoporos Int* 2005;16:713–6. [PubMed: 15776217]
5. King L, Dear K, Harrison SL, et al. Investigating the patterns and determinants of seasonal variation in vitamin D status in Australian adults: the Seasonal D Cohort Study. *BMC Public Health* 2016;16:892. [PubMed: 27565723]
6. Diffey BL. Modelling the seasonal variation of vitamin D due to sun exposure. *Br J Dermatol* 2010;162:1342–8. [PubMed: 20163416]
7. Campbell MJ. Vitamin D and the RNA transcriptome: more than mRNA regulation. *Front Physiol* 2014;5:181. [PubMed: 24860511]
8. Carlberg C, Campbell MJ. Vitamin D receptor signaling mechanisms: integrated actions of a well-defined transcription factor. *Steroids* 2013;78:127–36. [PubMed: 23178257]

9. Carlberg C. Molecular approaches for optimizing vitamin D supplementation. *Vitam Horm* 2016;100:255–71. [PubMed: 26827955]
10. Narvaez CJ, Matthews D, LaPorta E, et al. The impact of vitamin D in breast cancer: genomics, pathways, metabolism. *Front Physiol* 2014;5:213. [PubMed: 24982636]
11. White JH. Vitamin D metabolism and signaling in the immune system. *Rev Endocr Metab Disord* 2012;13:21–9. [PubMed: 21845364]
12. Bikle DD. Extraskelatal actions of vitamin D. *Ann N Y Acad Sci* 2016;1376:29–52. [PubMed: 27649525]
13. Jeffery LE, Raza K, Hewison M. Vitamin D in rheumatoid arthritis-towards clinical application. *Nat Rev Rheumatol* 2016;12:201–10. [PubMed: 26481434]
14. Brumbaugh PF, Hughes MR, Haussler MR. Cytoplasmic and nuclear binding components for 1 α ,25-dihydroxyvitamin D₃ in chick parathyroid glands. *Proc Natl Acad Sci U S A* 1975;72:4871–5. [PubMed: 1061076]
15. Jones PG, Haussler MR. Scintillation autoradiographic localization of 1,25-dihydroxyvitamin D₃ in chick intestine. *Endocrinology* 1979;104:313–21. [PubMed: 446363]
16. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D₃ and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. *Endocrinology* 1981;108:1083–6. [PubMed: 6257495]
17. Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. *Cell* 1978;15:393–403. [PubMed: 214238]
18. Raelson JV, Nervi C, Rosenauer A, et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. *Blood* 1996;88:2826–32. [PubMed: 8874178]
19. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemiaspecific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. *Cell* 1993;74:423–31. [PubMed: 8394219]
20. de The H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell* 1991;66:675–84. [PubMed: 1652369]
21. Chen SJ, Zhu YJ, Tong JH, et al. Rearrangements in the second intron of the RARA gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular marker for retinoic acid-induced leukemic cell differentiation. *Blood* 1991;78:2696–701. [PubMed: 1668609]
22. Douer D, Koeffler HP. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. *J Clin Invest* 1982;69:277–83. [PubMed: 6276439]
23. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. *Proc Natl Acad Sci U S A* 1980;77:2936–40. [PubMed: 6930676]
24. Castaigne S, Chomienne C, Daniel MT, et al. Retinoic acids in the treatment of acute promyelocytic leukemia. *Nouv Rev Fr Hematol* 1990;32:36–8. [PubMed: 2190178]
25. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. *Haematol Blood Transfus* 1989;32:88–96. [PubMed: 2696695]
26. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. *Nature* 1998;391:815–8. [PubMed: 9486655]
27. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. *Nature* 1998;391:811–4. [PubMed: 9486654]
28. Spira AI, Carducci MA. Differentiation therapy. *Curr Opin Pharmacol* 2003;3: 338–43. [PubMed: 12901941]
29. Ferrari AC, Waxman S. Differentiation agents in cancer therapy. *Cancer Chemo-ther Biol Response Modif* 1994;15:337–66.
30. Lo-Coco F, Di Donato L, GIMEMA, et al., German-Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia. Targeted therapy alone for acute promyelocytic leukemia. *N Engl J Med* 2016;374:1197–8. [PubMed: 27007970]

31. Uray IP, Dmitrovsky E, Brown PH. Retinoids and rexinoids in cancer prevention: from laboratory to clinic. *Semin Oncol* 2016;43:49–64. [PubMed: 26970124]
32. Bhutani T, Koo J. A review of the chemopreventative effects of oral retinoids for internal neoplasms. *J Drugs Dermatol* 2011;10:1292–8. [PubMed: 22052311]
33. Campbell MJ, Park S, Uskokovic MR, et al. Expression of retinoic acid receptorbeta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog. *Endocrinology* 1998;139:1972–80. [PubMed: 9528984]
34. Miyaura C, Abe E, Kuribayashi T, et al. 1 alpha,25-dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. *Biochem Biophys Res Commun* 1981;102:937–43. [PubMed: 6946774]
35. Abe E, Miyaura C, Sakagami H, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. *Proc Natl Acad Sci U S A* 1981;78:4990–4. [PubMed: 6946446]
36. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, et al. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. *Cancer Res* 2003;63:7799–806. [PubMed: 14633706]
37. Koike M, Elstner E, Campbell MJ, et al. 19-nor-hexafluoride analogue of vitamin D3: a novel class of potent inhibitors of proliferation of human breast cell lines. *Cancer Res* 1997;57:4545–50. [PubMed: 9377567]
38. Campbell MJ, Elstner E, Holden S, et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. *J Mol Endocrinol* 1997;19:15–27. [PubMed: 9278857]
39. Elstner E, Campbell MJ, Munker R, et al. Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. *Prostate* 1999;40:141–9. [PubMed: 10398275]
40. Peehl DM, Skowronski RJ, Leung GK, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. *Cancer Res* 1994; 54:805–10. [PubMed: 7508338]
41. Welsh J, Wietzke JA, Zinser GM, et al. Impact of the vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. *J Steroid Biochem Mol Biol* 2002;83:85–92. [PubMed: 12650704]
42. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. *Lancet* 1989;1:188–91. [PubMed: 2563099]
43. Colston K, Colston MJ, Fieldsteel AH, et al. 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. *Cancer Res* 1982;42:856–9. [PubMed: 6895862]
44. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70. [PubMed: 10647931]
45. Yen A, Varvayanis S. RB phosphorylation in sodium butyrate-resistant HL-60 cells: cross-resistance to retinoic acid but not vitamin D3. *J Cell Physiol* 1995; 163:502–9. [PubMed: 7775593]
46. Hager G, Formanek M, Gedlicka C, et al. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. *Acta Otolaryngol* 2001;121: 103–9. [PubMed: 11270487]
47. Kumagai T, O'Kelly J, Said JW, et al. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. *J Natl Cancer Inst* 2003;95:896–905. [PubMed: 12813173]
48. Davoust N, Wion D, Chevalier G, et al. Vitamin D receptor stable transfection restores the susceptibility to 1,25-dihydroxyvitamin D3 cytotoxicity in a rat glioma resistant clone. *J Neurosci Res* 1998;52:210–9. [PubMed: 9579411]
49. Fife RS, Sledge GW Jr, Proctor C. Effects of vitamin D3 on proliferation of cancer cells in vitro. *Cancer Lett* 1997;120:65–9. [PubMed: 9570387]
50. Naveilhan P, Berger F, Haddad K, et al. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors? *J Neurosci Res* 1994;37:271–7. [PubMed: 8151734]
51. Wang X, Studzinski GP. Antiapoptotic action of 1,25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c. *Exp Cell Res* 1997;235:210–7. [PubMed: 9281370]

52. Xu HM, Tepper CG, Jones JB, et al. 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. *Exp Cell Res* 1993;209:367–74. [PubMed: 8262155]
53. Liu M, Lee MH, Cohen M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. *Genes Dev* 1996;10:142–53. [PubMed: 8566748]
54. Saramaki A, Banwell CM, Campbell MJ, et al. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. *Nucleic Acids Res* 2006;34:543–54. [PubMed: 16434701]
55. Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. *Cancer Res* 1996;56:264–7. [PubMed: 8542578]
56. Li P, Li C, Zhao X, et al. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. *J Biol Chem* 2004;279:25260–7. [PubMed: 15075339]
57. Huang YC, Chen JY, Hung WC. Vitamin D(3) receptor/Sp1 complex is required for the induction of p27(Kip1) expression by vitamin D(3). *Oncogene* 2004; 23(28):4856–61. [PubMed: 15064717]
58. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. *Science* 1996;271:1861–4. [PubMed: 8596954]
59. Jiang F, Li P, Fornace AJ Jr, et al. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. *J Biol Chem* 2003;278:48030–40. [PubMed: 14506229]
60. Akutsu N, Lin R, Bastien Y, et al. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. *Mol Endocrinol* 2001;15:1127–39. [PubMed: 11435613]
61. Khanim FL, Gommersall LM, Wood VH, et al. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. *Oncogene* 2004;23: 6712–25. [PubMed: 15300237]
62. Wu G, Fan RS, Li W, et al. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. *Oncogene* 1997;15:1555–63. [PubMed: 9380407]
63. Lubbert M, Salser W, Prokocimer M, et al. Stable methylation patterns of MYC and other genes regulated during terminal myeloid differentiation. *Leukemia* 1991;5:533–9. [PubMed: 1649355]
64. Zhou JY, Norman AW, Lubbert M, et al. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization. *Blood* 1989;74:82–93. [PubMed: 2665845]
65. Zile MH, Cullum ME, Simpson RU, et al. Induction of differentiation of human promyelocytic leukemia cell line HL-60 by retinoyl glucuronide, a biologically active metabolite of vitamin A. *Proc Natl Acad Sci U S A* 1987;84:2208–12. [PubMed: 3470785]
66. Wang JK, Johnson MD, Morgan JI, et al. Vitamin D3 derivatives inhibit the differentiation of Friend erythroleukemia cells. *Mol Pharmacol* 1986;30:639–42. [PubMed: 3023814]
67. Brelvi ZS, Studzinski GP. Inhibition of DNA synthesis by an inducer of differentiation of leukemic cells, 1 alpha, 25 dihydroxy vitamin D3, precedes down regulation of the c-myc gene. *J Cell Physiol* 1986;128:171–9. [PubMed: 3755442]
68. Munker R, Norman A, Koeffler HP. Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. *J Clin Invest* 1986;78: 424–30. [PubMed: 3461004]
69. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. *J Cell Biol* 2001;154:369–87. [PubMed: 11470825]
70. Lazzaro G, Agadir A, Qing W, et al. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. *Eur J Cancer* 2000;36:780–6. [PubMed: 10762752]
71. Konety BR, Schwartz GG, Acierno JS Jr, et al. The role of vitamin D in normal prostate growth and differentiation. *Cell Growth Differ* 1996;7:1563–70. [PubMed: 8930406]

72. Kim YR, Abraham NG, Lutton JD. Mechanisms of differentiation of U937 leukemic cells induced by GM-CSF and 1,25(OH)₂ vitamin D₃. *Leuk Res* 1991;15:409–18. [PubMed: 1861527]
73. Narvaez CJ, Byrne BM, Romu S, et al. Induction of apoptosis by 1,25-dihydroxyvitamin D₃ in MCF-7 vitamin D₃-resistant variant can be sensitized by TPA. *J Steroid Biochem Mol Biol* 2003;84:199–209. [PubMed: 12711004]
74. Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D₃ and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. *Cancer Res* 2000;60:2304–12. [PubMed: 10786699]
75. Elstner E, Linker-Israeli M, Le J, et al. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D₃ analogs and 9-cis retinoic acid. *J Clin Invest* 1997;99:349–60. [PubMed: 9006004]
76. Elstner E, Linker-Israeli M, Said J, et al. 20-epi-vitamin D₃ analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. *Cancer Res* 1995;55:2822–30. [PubMed: 7796409]
77. Narvaez CJ, Vanweelden K, Byrne I, et al. Characterization of a vitamin D₃-resistant MCF-7 cell line. *Endocrinology* 1996;137:400–9. [PubMed: 8593782]
78. Byrne BM, Welsh J. Altered thioredoxin subcellular localization and redox status in MCF-7 cells following 1,25-dihydroxyvitamin D₃ treatment. *J Steroid Biochem Mol Biol* 2005;97:57–64. [PubMed: 16061374]
79. Jeon JH, Lee KN, Hwang CY, et al. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. *Cancer Res* 2005;65:4485–9. [PubMed: 15930262]
80. Junn E, Han SH, Im JY, et al. Vitamin D₃ up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. *J Immunol* 2000;164: 6287–95. [PubMed: 10843682]
81. Ferrer-Mayorga G, Gomez-Lopez G, Barbachano A, et al. Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. *Gut* 2017;66(8):1449–62. [PubMed: 27053631]
82. Alvarez-Diaz S, Valle N, Garcia JM, et al. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. *J Clin Invest* 2009;119:2343–58. [PubMed: 19662683]
83. Pendas-Franco N, Garcia JM, Pena C, et al. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D₃. *Oncogene* 2008;27:4467–77. [PubMed: 18408752]
84. Larriba MJ, Valle N, Palmer HG, et al. The inhibition of Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D₃ is abrogated by Snail1 in human colon cancer cells. *Endocr Relat Cancer* 2007;14:141–51. [PubMed: 17395983]
85. Palmer HG, Larriba MJ, Garcia JM, et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. *Nat Med* 2004;10:917–9. [PubMed: 15322538]
86. Tenbaum SP, Ordonez-Moran P, Puig I, et al. Beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. *Nat Med* 2012;18:892–901. [PubMed: 22610277]
87. Chiang KC, Yeh CN, Hsu JT, et al. The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells. *Cancer Lett* 2014;354:235–44. [PubMed: 25149065]
88. Upadhyay SK, Verone A, Shoemaker S, et al. 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) signaling capacity and the epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC): implications for use of 1,25(OH)₂D₃ in NSCLC treatment. *Cancers (Basel)* 2013;5:1504–21. [PubMed: 24217116]
89. Gniadecki R, Gajkowska B, Hansen M. 1,25-dihydroxyvitamin D₃ stimulates the assembly of adherens junctions in keratinocytes: involvement of protein kinase C. *Endocrinology* 1997;138:2241–8. [PubMed: 9165007]
90. Prudencio J, Akutsu N, Benlimame N, et al. Action of low calcemic 1alpha,25-dihydroxyvitamin D₃ analogue EB1089 in head and neck squamous cell carcinoma. *J Natl Cancer Inst* 2001;93:745–53. [PubMed: 11353784]

91. Baudet C, Chevalier G, Chassevent A, et al. 1,25-dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. *J Neurosci Res* 1996;46:540–50. [PubMed: 8951666]
92. Asada M, Yamada T, Fukumuro K, et al. p21Cip1/WAF1 is important for differentiation and survival of U937 cells. *Leukemia* 1998;12:1944–50. [PubMed: 9844924]
93. Munker R, Kobayashi T, Elstner E, et al. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. *Blood* 1996;88:2201–9. [PubMed: 8822940]
94. Schwaller J, Koeffler HP, Niklaus G, et al. Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. *J Clin Invest* 1995;95:973–9. [PubMed: 7883998]
95. Stambolsky P, Tabach Y, Fontemaggi G, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. *Cancer Cell* 2010;17:273–85. [PubMed: 20227041]
96. Reichrath J, Reichrath S, Heyne K, et al. Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling. *Front Physiol* 2014;5:166. [PubMed: 24917821]
97. Ellison TI, Smith MK, Gilliam AC, et al. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. *J Invest Dermatol* 2008;128:2508–17. [PubMed: 18509362]
98. Graziano S, Johnston R, Deng O, et al. Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence. *Oncogene* 2016;35: 5362–76. [PubMed: 27041576]
99. Pickholtz I, Saadyan S, Keshet GI, et al. Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells. *Oncotarget* 2014;5: 11827–46. [PubMed: 25460500]
100. Campbell MJ, Gombart AF, Kwok SH, et al. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. *Oncogene* 2000;19:5091–7. [PubMed: 11042697]
101. Eelen G, Verlinden L, Van Camp M, et al. Microarray analysis of 1alpha,25-dihydroxyvitamin D3-treated MC3T3-E1 cells. *J Steroid Biochem Mol Biol* 2004; 89–90:405–7.
102. Wang TT, Tavera-Mendoza LE, Laperriere D, et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. *Mol Endocrinol* 2005;19(11):2685–95. [PubMed: 16002434]
103. Savli H, Aalto Y, Nagy B, et al. Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: a cDNA array study. *Br J Haematol* 2002;118:1065–70. [PubMed: 12199786]
104. Lin R, Nagai Y, Sladek R, et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. *Mol Endocrinol* 2002;16: 1243–56. [PubMed: 12040012]
105. Ferreira GB, Vanherwegen AS, Eelen G, et al. Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways. *Cell Rep* 2015 [Epub ahead of print].
106. Bosse Y, Maghni K, Hudson TJ. 1alpha,25-dihydroxy-vitamin D3 stimulation of bronchial smooth muscle cells induces autocrine, contractility, and remodeling processes. *Physiol Genomics* 2007;29:161–8. [PubMed: 17213369]
107. Kawata H, Kamiakito T, Takayashiki N, et al. Vitamin D3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8. *J Cell Physiol* 2006;207: 793–9. [PubMed: 16508948]
108. Guzey M, Luo J, Getzenberg RH. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells. *J Cell Biochem* 2004;93:271–85. [PubMed: 15368355]
109. Kobayashi T, Uehara S, Ikeda T, et al. Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells. *Kidney Int* 2003;64:1632–42. [PubMed: 14531794]
110. Hilpert J, Wogensen L, Thykjaer T, et al. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism. *Kidney Int* 2002;62: 1672–81. [PubMed: 12371967]
111. Takahashi Y, Nagata T, Ishii Y, et al. Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. *Oncol Rep* 2002;9:75–9. [PubMed: 11748459]

112. Townsend K, Trevino V, Falciani F, et al. Identification of VDR-responsive gene signatures in breast cancer cells. *Oncology* 2006;71:111–23. [PubMed: 17377416]
113. Larsen JE, Nathan V, Osborne JK, et al. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. *J Clin Invest* 2016;126:3219–35. [PubMed: 27500490]
114. Tagliafico E, Tenedini E, Manfredini R, et al. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. *Leukemia* 2006;20:1751–8. [PubMed: 16932344]
115. Engreitz JM, Chen R, Morgan AA, et al. ProfileChaser: searching microarray repositories based on genome-wide patterns of differential expression. *Bioinformatics* 2011;27:3317–8. [PubMed: 21967760]
116. Shah NH, Jonquet C, Chiang AP, et al. Ontology-driven indexing of public datasets for translational bioinformatics. *BMC Bioinformatics* 2009;10(Suppl 2):S1.
117. Jiang YJ, Bikle DD. LncRNA: a new player in 1 α , 25(OH) $_2$ vitamin D $_3$ /VDR protection against skin cancer formation. *Exp Dermatol* 2014;23:147–50. [PubMed: 24499465]
118. Singh PK, Long MD, Battaglia S, et al. VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription. *Epigenetics* 2015;10:40–9. [PubMed: 25494645]
119. Ding N, Yu RT, Subramaniam N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. *Cell* 2013;153:601–13. [PubMed: 23622244]
120. Heikkinen S, Vaisanen S, Pehkonen P, et al. Nuclear hormone 1 α ,25-dihydroxyvitamin D $_3$ elicits a genome-wide shift in the locations of VDR chromatin occupancy. *Nucleic Acids Res* 2011;39:9181–93. [PubMed: 21846776]
121. Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. *Mol Endocrinol* 2012;26:37–51. [PubMed: 22108803]
122. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. *Genome Res* 2010;20:1352–60. [PubMed: 20736230]
123. Tuoresmaki P, Vaisanen S, Neme A, et al. Patterns of genome-wide VDR locations. *PLoS One* 2014;9:e96105. [PubMed: 24787735]
124. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. *Nature* 2012;489:101–8. [PubMed: 22955620]
125. Shaffer PL, Gewirth DT. Structural analysis of RXR-VDR interactions on DR3 DNA. *J Steroid Biochem Mol Biol* 2004;89–90:215–9.
126. Sasaki H, Harada H, Handa Y, et al. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. *Biochemistry* 1995; 34:370–7. [PubMed: 7819220]
127. Nayeri S, Danielsson C, Kahlen JP, et al. The anti-proliferative effect of vitamin D $_3$ analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity. *Oncogene* 1995;11:1853–8. [PubMed: 7478614]
128. Quack M, Carlberg C. Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. *Mol Pharmacol* 1999;55: 1077–87. [PubMed: 10347251]
129. Phan TQ, Jow MM, Privalsky ML. DNA recognition by thyroid hormone and retinoic acid receptors: 3,4,5 rule modified. *Mol Cell Endocrinol* 2010;319:88–98. [PubMed: 19945505]
130. Lun AT, Smyth GK. From reads to regions: a bioconductor workflow to detect differential binding in ChIP-seq data. *F1000Res* 2015;4:1080. [PubMed: 26834993]
131. Yoon JS, Kim JY, Park HK, et al. Antileukemic effect of a synthetic vitamin D $_3$ analog, HY-11, with low potential to cause hypercalcemia. *Int J Oncol* 2008; 32:387–96. [PubMed: 18202761]
132. Vaisanen S, Perakyla M, Karkkainen JI, et al. Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor. *Mol Pharmacol* 2003;63:1230–7. [PubMed: 12761332]
133. Peleg S, Ismail A, Uskokovic MR, et al. Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26–9228, a noncalcemic analog of vitamin D $_3$. *J Cell Biochem* 2003;88:267–73. [PubMed: 12520525]

134. Evans SR, Soldatenkov V, Shchepotin EB, et al. Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25–6760) inhibits human colon cancer in vitro via apoptosis. *Int J Oncol* 1999;14:979–85. [PubMed: 10200351]
135. Takahashi F, Finch JL, Denda M, et al. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. *Am J Kidney Dis* 1997;30:105–12. [PubMed: 9214408]
136. O’Kelly J, Uskokovic M, Lemp N, et al. Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. *J Steroid Biochem Mol Biol* 2006;100:107–16. [PubMed: 16777406]
137. Zhou JY, Norman AW, Akashi M, et al. Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. *Blood* 1991;78:75–82. [PubMed: 1648977]
138. Belorusova AY, Rochel N. Structural studies of vitamin D nuclear receptor ligand-binding properties. *Vitam Horm* 2016;100:83–116. [PubMed: 26827949]
139. Eelen G, Valle N, Sato Y, et al. Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. *Chem Biol* 2008;15:1029–34. [PubMed: 18940664]
140. Eelen G, Verlinden L, Rochel N, et al. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. *Mol Pharmacol* 2005;67:1566–73. [PubMed: 15728261]
141. Amling M, Priemel M, Holzmann T, et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. *Endocrinology* 1999;140:4982–7. [PubMed: 10537122]
142. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. *Proc Natl Acad Sci U S A* 2001;98:13324–9. [PubMed: 11687634]
143. Kallay E, Pietschmann P, Toyokuni S, et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. *Carcinogenesis* 2001;22:1429–35. [PubMed: 11532865]
144. Jin D, Wu S, Zhang YG, et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. *Clin Ther* 2015;37: 996–1009.e7. [PubMed: 26046242]
145. Zinser GM, Welsh J. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. *Carcinogenesis* 2004;25: 2361–72. [PubMed: 15333467]
146. Zinser GM, Sundberg JP, Welsh J. Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. *Carcinogenesis* 2002;23:2103–9. [PubMed: 12507934]
147. Larriba MJ, Ordonez-Moran P, Chicote I, et al. Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. *PLoS One* 2011;6:e23524. [PubMed: 21858154]
148. Teichert AE, Elalieh H, Elias PM, et al. Overexpression of hedgehog signaling is associated with epidermal tumor formation in vitamin D receptor-null mice. *J Invest Dermatol* 2011;131:2289–97. [PubMed: 21814234]
149. Colston KW, Chander SK, Mackay AG, et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. *Biochem Pharmacol* 1992;44:693–702. [PubMed: 1324683]
150. Oades GM, Dredge K, Kirby RS, et al. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. *BJU Int* 2002;90:607–16. [PubMed: 12230626]
151. Zugmaier G, Jager R, Grage B, et al. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. *Br J Cancer* 1996;73: 1341–6. [PubMed: 8645577]
152. El Abdaimi K, Dion N, Papavasiliou V, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. *Cancer Res* 2000;60:4412–8. [PubMed: 10969786]

153. Li Z, Jia Z, Gao Y, et al. Activation of vitamin D receptor signaling down-regulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. *Clin Cancer Res* 2015;21:844–53. [PubMed: 25501129]
154. Zhang X, Jiang F, Li P, et al. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. *Clin Cancer Res* 2005;11:323–8. [PubMed: 15671562]
155. Dackiw AP, Ezzat S, Huang P, et al. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. *Endocrinology* 2004;145: 5840–6. [PubMed: 15319350]
156. Kim JS, Roberts JM, Bingman WE 3rd, et al. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. *Endocrinology* 2014;155:3262–73. [PubMed: 24926821]
157. Tangpricha V, Spina C, Yao M, et al. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. *J Nutr* 2005;135:2350–4. [PubMed: 16177194]
158. Peleg S, Khan F, Navone NM, et al. Inhibition of prostate cancer-mediated osteoblastic bone lesions by the low-calcemic analog 1 α -hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3. *J Steroid Biochem Mol Biol* 2005; 97:203–11. [PubMed: 16081281]
159. Verone-Boyle AR, Shoemaker S, Attwood K, et al. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo. *Oncotarget* 2016;7:995–1013. [PubMed: 26654942]
160. Newmark HL, Yang K, Kurihara N, et al. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. *Carcinogenesis* 2009;30:88–92. [PubMed: 19017685]
161. Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. *Gut* 1992;33: 1660–3. [PubMed: 1336758]
162. Cross HS, Nittke T, Kallay E. Colonic vitamin D metabolism: implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. *Mol Cell Endocrinol* 2011;347:70–9. [PubMed: 21801808]
163. Kallay E, Bises G, Bajna E, et al. Colon-specific regulation of vitamin D hydroxylases—a possible approach for tumor prevention. *Carcinogenesis* 2005;26: 1581–9. [PubMed: 15905206]
164. Cross HS, Kallay E, Lechner D, et al. Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. *J Nutr* 2004;134:1207S–12S. [PubMed: 15113973]
165. Aggarwal A, Kallay E. Cross talk between the calcium-sensing receptor and the vitamin D system in prevention of cancer. *Front Physiol* 2016;7:451. [PubMed: 27803671]
166. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D for cancer prevention: global perspective. *Ann Epidemiol* 2009;19:468–83. [PubMed: 19523595]
167. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. *J Steroid Biochem Mol Biol* 2007;103:708–11. [PubMed: 17368188]
168. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. *J Steroid Biochem Mol Biol* 2005;97:179–94. [PubMed: 16236494]
169. Garland C, Shekelle RB, Barrett-Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. *Lancet* 1985; 1:307–9. [PubMed: 2857364]
170. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? *Int J Epidemiol* 1980;9:227–31. [PubMed: 7440046]
171. Engel P, Fagherazzi G, Boutten A, et al. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. *Cancer Epidemiol Biomarkers Prev* 2010;19:2341–50. [PubMed: 20826834]
172. Chen P, Hu P, Xie D, et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. *Breast Cancer Res Treat* 2010;121:469–77. [PubMed: 19851861]
173. Abbas S, Linseisen J, Slinger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer—results of a large case-control study. *Carcinogenesis* 2008;29:93–9. [PubMed: 17974532]

174. Vrieling A, Seibold P, Johnson TS, et al. Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: influence of tumor characteristics and lifestyle factors? *Int J Cancer* 2014;134:2972–83. [PubMed: 24272459]
175. Meeker S, Seamons A, Maggio-Price L, et al. Protective links between vitamin D, inflammatory bowel disease and colon cancer. *World J Gastroenterol* 2016;22: 933–48. [PubMed: 26811638]
176. Shirazi L, Almquist M, Borgquist S, et al. Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: a nested case-control study. *Breast* 2016;28:184–90. [PubMed: 27326980]
177. Yao S, Kwan ML, Ergas IJ, et al. Association of serum level of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study. *JAMA Oncol* 2017;3:351–7. [PubMed: 27832250]
178. Yuan C, Qian ZR, Babic A, et al. Prediagnostic plasma 25-hydroxyvitamin D and pancreatic cancer survival. *J Clin Oncol* 2016;34:2899–905. [PubMed: 27325858]
179. Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. *J Clin Oncol* 2014;32:3242–8. [PubMed: 25135997]
180. Choo CS, Mamedov A, Chung M, et al. Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. *Nutr Res* 2011;31:21–6. [PubMed: 21310302]
181. Bonjour JP, Chevalley T, Fardellone P. Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer. *Br J Nutr* 2007;97: 611–6. [PubMed: 17349071]
182. Shui IM, Mondul AM, Lindstrom S, et al., Breast and Prostate Cancer Cohort Consortium Group. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. *Cancer* 2015;121:1949–56. [PubMed: 25731953]
183. Holt SK, Kolb S, Fu R, et al. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. *Cancer Epidemiol* 2013;37:666–70. [PubMed: 23972671]
184. Albanes D, Mondul AM, Yu K, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. *Cancer Epidemiol Biomarkers Prev* 2011;20:1850–60. [PubMed: 21784952]
185. Park SY, Cooney RV, Wilkens LR, et al. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. *Eur J Cancer* 2010;46:932–6. [PubMed: 20064705]
186. Jacot W, Firmin N, Roca L, et al. Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study. *Ann Oncol* 2016;27:1235–41. [PubMed: 27029707]
187. Bassuk SS, Manson JE, Lee IM, et al. Baseline characteristics of participants in the VITamin D and omega-3 Trial (VITAL). *Contemp Clin Trials* 2016;47:235–43. [PubMed: 26767629]
188. Flarakos CC, Weiskopf A, Robinson M, et al. Metabolism of selective 20-epi-vitamin D3 analogs in rat osteosarcoma UMR-106 cells: isolation and identification of four novel C-1 fatty acid esters of 1alpha,25-dihydroxy-16-ene-20-epi-vitamin D3. *Steroids* 2017;119:18–30. [PubMed: 28089927]
189. Okamoto R, Gery S, Kuwayama Y, et al. Novel Gemini vitamin D3 analogs: large structure/function analysis and ability to induce antimicrobial peptide. *Int J Cancer* 2014;134:207–17. [PubMed: 23775785]
190. Huet T, Maehr H, Lee HJ, et al. Structure-function study of gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097. *Medchemcomm* 2011;2:424–9. [PubMed: 22180837]
191. Reddy GS, Omdahl JL, Robinson M, et al. 23-carboxy-24,25,26,27-tetranorvitamin D3 (calcioic acid) and 24-carboxy-25,26,27-trinorvitamin D3 (cholacalcioic acid): end products of 25-hydroxyvitamin D3 metabolism in rat kidney through C-24 oxidation pathway. *Arch Biochem Biophys* 2006;455:18–30. [PubMed: 17027908]
192. Uskokovic MR, Manchand P, Marczak S, et al. C-20 cyclopropyl vitamin D3 analogs. *Curr Top Med Chem* 2006;6:1289–96. [PubMed: 16848742]
193. Weinstein EA, Rao DS, Siu-Caldera ML, et al. Isolation and identification of 1alpha-hydroxy-24-oxovitamin D3 and 1alpha,23-dihydroxy-24-oxovitamin D3: metabolites of 1alpha,24(R)-

- dihydroxyvitamin D3 produced in rat kidney. *Biochem Pharmacol* 1999;58:1965–73. [PubMed: 10591152]
194. Sekimoto H, Siu-Caldera ML, Weiskopf A, et al. 1alpha,25-dihydroxy-3-epivitamin D3: in vivo metabolite of 1alpha,25-dihydroxyvitamin D3 in rats. *FEBS Lett* 1999;448:278–82. [PubMed: 10218492]
195. Gardner JP, Zhang F, Uskokovic MR, et al. Vitamin D analog 25-(OH)-16,23E-Diene-26,27-hexafluoro-vitamin D3 induces differentiation of HL60 cells with minimal effects on cellular calcium homeostasis. *J Cell Biochem* 1996;63: 500–12. [PubMed: 8978465]
196. Rao LG, Sutherland MK, Reddy GS, et al. Effects of 1alpha,25-dihydroxy-16ene, 23yne-vitamin D3 on osteoblastic function in human osteosarcoma SaOS-2 cells: differentiation-stage dependence and modulation by 17-beta estradiol. *Bone* 1996;19:621–7. [PubMed: 8968029]
197. Napoli JL, Sommerfeld JL, Pramanik BC, et al. 19-nor-10-ketovitamin D derivatives: unique metabolites of vitamin D3, vitamin D2, and 25-hydroxyvitamin D3. *Biochemistry* 1983;22:3636–40. [PubMed: 6311251]
198. Reinhardt TA, Napoli JL, Praminik B, et al. 1 Alpha-25,26-trihydroxyvitamin D3: an in vivo and in vitro metabolite of vitamin D3. *Biochemistry* 1981;20:6230–5. [PubMed: 6272836]
199. Narwid TA, Blount JF, Iacobelli JA, et al. Vitamin D3 metabolites. 3. Synthesis and X-ray analysis of 1 alpha,25-dihydroxycholesterol. *Helv Chim Acta* 1974; 57:781–9. [PubMed: 4364578]
200. Asou H, Koike M, Elstner E, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. *Blood* 1998;92:2441–9. [PubMed: 9746784]
201. Maenpaa PH, Vaisanen S, Jaaskelainen T, et al. Vitamin D(3) analogs (MC 1288, KH 1060, EB 1089, GS 1558, and CB 1093): studies on their mechanism of action. *Steroids* 2001;66:223–5. [PubMed: 11179729]
202. Wang X, Chen X, Akhter J, et al. The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). *Br J Urol* 1997;80:260–2. [PubMed: 9284199]
203. Akhter J, Goerdel M, Morris DL. Vitamin D3 analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells. *Br J Surg* 1996;83:229–30. [PubMed: 8689173]
204. Mathiasen IS, Colston KW, Binderup L. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. *J Steroid Biochem Mol Biol* 1993;46:365–71. [PubMed: 9831485]
205. Sundaram S, Beckman MJ, Bajwa A, et al. QW-1624F2–2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other dexamethasone and suppresses the invasiveness of human metastatic breast tumor cells. *Mol Cancer Ther* 2006;5:2806–14. [PubMed: 17121927]
206. Kahraman M, Sinishtaj S, Dolan PM, et al. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). *J Med Chem* 2004;47:6854–63. [PubMed: 15615534]
207. Somjen D, Waisman A, Lee JK, et al. A non-calcemic analog of 1 alpha,25 dihydroxy vitamin D(3) (JKF) upregulates the induction of creatine kinase B by 17 beta estradiol in osteoblast-like ROS 17/2.8 cells and in rat diaphysis. *J Steroid Biochem Mol Biol* 2001;77:205–12. [PubMed: 11457658]
208. Posner GH. New vitamin D analogues. *Nephrol Dial Transplant* 1996;11(Suppl 3):32–6.
209. Gulliford T, English J, Colston KW, et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. *Br J Cancer* 1998;78:6–13. [PubMed: 9662243]
210. Jain RK, Trump DL, Egorin MJ, et al. A phase I study of the vitamin D3 analogue ILX23–7553 administered orally to patients with advanced solid tumors. *Invest New Drugs* 2011;29:1420–5. [PubMed: 20661623]
211. Evans TR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. *Br J Cancer* 2002;86:680–5. [PubMed: 11875725]

212. Dalhoff K, Dancy J, Astrup L, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. *Br J Cancer* 2003;89:252–7. [PubMed: 12865912]
213. Flaig TW, Barqawi A, Miller G, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. *Cancer* 2006;107:266–74. [PubMed: 16779800]
214. Jarrard D, Konety B, Huang W, et al. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. *Am J Clin Exp Urol* 2016;4:17–27. [PubMed: 27766277]
215. Chadha MK, Tian L, Mashtare T, et al. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. *Cancer* 2010;116:2132–9. [PubMed: 20166215]
216. Osborn JL, Schwartz GG, Smith DC, et al. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. *Urol Oncol* 1995;1: 195–8. [PubMed: 21224117]
217. Amir E, Simmons CE, Freedman OC, et al. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. *Cancer* 2010;116:284–91. [PubMed: 19918922]
218. Beer TM, Myrthue A, Garzotto M, et al. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. *Cancer Epidemiol Biomarkers Prev* 2004;13:2225–32. [PubMed: 15598784]
219. Wagner D, Trudel D, Van der Kwast T, et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. *J Clin Endocrinol Metab* 2013;98:1498–507. [PubMed: 23463655]
220. Beer TM, Ryan CW, Venner PM, et al., ASCENT (AIPC Study of Calcitriol ENhancing Taxotere) Investigators. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. *Cancer* 2008;112:326–30. [PubMed: 17960793]
221. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. *J Clin Oncol* 2011;29:2191–8. [PubMed: 21483004]
222. Stahel R, Bogaerts J, Ciardiello F, et al. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. *Cancer Treat Rev* 2015;41:129–35. [PubMed: 25533737]
223. Leichman L, Groshen S, O’Neil BH, et al. Phase II study of olaparib (AZD-2281) after standard systemic therapies for disseminated colorectal cancer. *Oncologist* 2016;21:172–7. [PubMed: 26786262]
224. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet Oncol* 2016;17:1579–89. [PubMed: 27617661]
225. Guha M. PARP inhibitors stumble in breast cancer. *Nat Biotechnol* 2011;29: 373–4. [PubMed: 21552220]
226. Martin M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. *J Clin Oncol* 2015; 33:1045–52. [PubMed: 25691671]
227. Sharma SP. Avastin saga reveals debate over clinical trial endpoints. *J Natl Cancer Inst* 2012;104:800–1. [PubMed: 22673590]
228. Azvolinsky A. PARP inhibitors: targeting the right patients. *J Natl Cancer Inst* 2012;104:1851–2. [PubMed: 23231976]

229. Bang YJ, Im SA, Lee KW, et al. Double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. *J Clin Oncol* 2015;33:3858–65. [PubMed: 26282658]
230. Tworoger SS, Gates MA, Lee IM, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. *Cancer Res* 2009;69:1885–91. [PubMed: 19223536]
231. Murtaugh MA, Sweeney C, Ma KN, et al. Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. *Nutr Cancer* 2006;55:35–43. [PubMed: 16965239]
232. Buyru N, Tezol A, Yosunkaya-Fenerci E, et al. Vitamin D receptor gene polymorphisms in breast cancer. *Exp Mol Med* 2003;35:550–5. [PubMed: 14749534]
233. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. *J Natl Cancer Inst* 1997;89:166–70. [PubMed: 8998186]
234. Bretherton-Watt D, Given-Wilson R, Mansi JL, et al. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. *Br J Cancer* 2001;85:171–5. [PubMed: 11461072]
235. Gu H, Wang X, Zheng L, et al. Vitamin D receptor gene polymorphisms and esophageal cancer risk in a Chinese population: a negative study. *Med Oncol* 2014;31:827. [PubMed: 24381141]
236. Kang S, Zhao Y, Liu J, et al. Association of vitamin D receptor Fok I polymorphism with the risk of prostate cancer: a meta-analysis. *Oncotarget* 2016;7: 77878–89. [PubMed: 27788484]
237. Lu D, Jing L, Zhang S. Vitamin D receptor polymorphism and breast cancer risk: a meta-analysis. *Medicine (Baltimore)* 2016;95:e3535. [PubMed: 27149457]
238. Clendenen TV, Ge W, Koenig KL, et al. Genetic polymorphisms in vitamin D metabolism and signaling genes and risk of breast cancer: a nested case-control study. *PLoS One* 2015;10:e0140478. [PubMed: 26488576]
239. Ashmore JH, Gallagher CJ, Lesko SM, et al. No association between vitamin D intake, VDR polymorphisms, and colorectal cancer in a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 2015;24:1635–7. [PubMed: 26224799]
240. Yang B, Liu S, Yang X, et al. Current evidence on the four polymorphisms of VDR and breast cancer risk in Caucasian women. *Meta Gene* 2014;2:41–9. [PubMed: 25606388]
241. Zhang Q, Shan Y. Genetic polymorphisms of vitamin D receptor and the risk of prostate cancer: a meta-analysis. *J BUON* 2013;18:961–9. [PubMed: 24344024]
242. Luo S, Guo L, Li Y, et al. Vitamin D receptor gene ApaI polymorphism and breast cancer susceptibility: a meta-analysis. *Tumour Biol* 2014;35:785–90. [PubMed: 24048755]
243. Perry JR, Day F, Elks CE, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* 2014;514:92–7. [PubMed: 25231870]
244. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012;491: 119–24. [PubMed: 23128233]
245. Lai HM, Chen CJ, Su BY, et al. Gout and type 2 diabetes have a mutual interdependent effect on genetic risk factors and higher incidences. *Rheumatology (Oxford)* 2012;51:715–20. [PubMed: 22179738]
246. Rennstam K, Jonsson G, Tanner M, et al. Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. *Cancer Genet Cytogenet* 2007;172:95–106. [PubMed: 17213017]
247. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. *Nat Genet* 2000;25:144–6. [PubMed: 10835626]
248. Lopes N, Sousa B, Martins D, et al. Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. *BMC Cancer* 2010;10:483. [PubMed: 20831823]
249. Holick CN, Stanford JL, Kwon EM, et al. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16:1990–9. [PubMed: 17932346]

250. Brozek W, Manhardt T, Kallay E, et al. Relative expression of vitamin D hydroxylases, CYP27B1 and CYP24A1, and of cyclooxygenase-2 and heterogeneity of human colorectal cancer in relation to age, gender, tumor location, and malignancy: results from factor and cluster analysis. *Cancers (Basel)* 2012;4:763–76. [PubMed: 24213465]
251. Cross HS, Kallay E, Farhan H, et al. Regulation of extrarenal vitamin D metabolism as a tool for colon and prostate cancer prevention. *Recent Results Cancer Res* 2003;164:413–25. [PubMed: 12899539]
252. Singh R, Yadav V, Kumar S, et al. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. *Sci Rep* 2015;5:17454. [PubMed: 26632252]
253. Ma JF, Nonn L, Campbell MJ, et al. Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. *Mol Cell Endocrinol* 2004;221: 67–74. [PubMed: 15223133]
254. Townsend K, Banwell CM, Guy M, et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. *Clin Cancer Res* 2005;11:3579–86. [PubMed: 15867263]
255. Peng X, Tiwari N, Roy S, et al. Regulation of CYP24 splicing by 1,25-dihydroxyvitamin D(3) in human colon cancer cells. *J Endocrinol* 2012;212:207–15. [PubMed: 22068926]
256. Doig CL, Singh PK, Dhiman VK, et al. Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. *Carcinogenesis* 2013;34:248–56. [PubMed: 23087083]
257. Meyer MB, Pike JW. Corepressors (NCoR and SMRT) as well as coactivators are recruited to positively regulated 1alpha,25-dihydroxyvitamin D3-responsive genes. *J Steroid Biochem Mol Biol* 2013;136:120–4. [PubMed: 22944139]
258. Abedin SA, Thorne JL, Battaglia S, et al. Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. *Carcinogenesis* 2009;30:449–56. [PubMed: 19126649]
259. Saramaki A, Diermeier S, Kellner R, et al. Cyclical chromatin looping and transcription factor association on the regulatory regions of the p21 (CDKN1A) gene in response to 1alpha,25-dihydroxyvitamin D3. *J Biol Chem* 2009;284: 8073–82. [PubMed: 19122196]
260. Peng X, Jhaveri P, Hussain-Hakimjee EA, et al. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5. *Carcinogenesis* 2007;28:1000–7. [PubMed: 17130524]
261. Tse AK, Zhu GY, Wan CK, et al. 1alpha,25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. *Mol Immunol* 2010;47:1728–38. [PubMed: 20371119]
262. Tavera-Mendoza LE, Quach TD, Dabbas B, et al. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. *Proc Natl Acad Sci U S A* 2008;105:8250–5. [PubMed: 18550844]
263. Rashid SF, Moore JS, Walker E, et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. *Oncogene* 2001;20:1860–72. [PubMed: 11313934]
264. Daniel C, Schroder O, Zahn N, et al. The TGFbeta/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression. *J Cell Biochem* 2007;102:1420–31. [PubMed: 17471513]
265. Gaschott T, Werz O, Steinmeyer A, et al. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. *Biochem Biophys Res Commun* 2001;288:690–6. [PubMed: 11676498]
266. Gaschott T, Wächtershäuser A, Steinhilber D, et al. 1,25-Dihydroxycholecalciferol enhances butyrate-induced p21(Waf1/Cip1) expression. *Biochem Biophys Res Commun* 2001;283:80–5. [PubMed: 11322770]
267. Malinen M, Saramaki A, Ropponen A, et al. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3. *Nucleic Acids Res* 2008;36: 121–32. [PubMed: 17999998]
268. Roberts L, Davenport RJ, Pennisi E, et al. A history of the human genome project. *Science* 2001;291:1195. [PubMed: 11233436]

269. Birney E. The making of ENCODE: lessons for big-data projects. *Nature* 2012; 489:49–51. [PubMed: 22955613]
270. ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* 2007;447:799–816. [PubMed: 17571346]
271. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, et al. Integrative analysis of 111 reference human epigenomes. *Nature* 2015;518: 317–30. [PubMed: 25693563]
272. Sanli K, Karlsson FH, Nookaew I, et al. FANTOM: functional and taxonomic analysis of metagenomes. *BMC Bioinformatics* 2013;14:38. [PubMed: 23375020]
273. Bujold D, Morais DA, Gauthier C, et al. The International human epigenome consortium data portal. *Cell Syst* 2016;3:496–9.e2. [PubMed: 27863956]
274. Chen L, Ge B, Casale FP, et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. *Cell* 2016;167:1398–414.e24. [PubMed: 27863251]
275. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet* 2013;45: 1113–20. [PubMed: 24071849]
276. Mele M, Ferreira PG, Reverter F, et al. Human genomics. The human transcriptome across tissues and individuals. *Science* 2015;348:660–5. [PubMed: 25954002]
277. Consortium GTEx. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580–5. [PubMed: 23715323]
278. Martelotto LG, De Filippo MR, Ng CK, et al. Genomic landscape of adenoid cystic carcinoma of the breast. *J Pathol* 2015;237:179–89. [PubMed: 26095796]
279. Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. *Nat Genet* 2013;45:791–8. [PubMed: 23685749]
280. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012;2:401–4. [PubMed: 22588877]
281. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 2013;6:p11. [PubMed: 23550210]
282. Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell* 2011;144: 296–309. [PubMed: 21241896]
283. Fuhrken PG, Chen C, Apostolidis PA, et al. Gene Ontology-driven transcriptional analysis of CD341 cell-initiated megakaryocytic cultures identifies new transcriptional regulators of megakaryopoiesis. *Physiol Genomics* 2008;33:159–69. [PubMed: 18252802]
284. Yetgin S, Ozsoylu S. Myeloid metaplasia in vitamin D deficiency rickets. *Scand J Haematol* 1982;28:180–5. [PubMed: 6979773]
285. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. *Blood* 1983;62:709–21. [PubMed: 6192859]
286. Mvubu NE, Pillay B, Gamielien J, et al. Canonical pathways, networks and transcriptional factor regulation by clinical strains of *Mycobacterium tuberculosis* in pulmonary alveolar epithelial cells. *Tuberculosis (Edinb)* 2016;97:73–85. [PubMed: 26980499]
287. Sims AC, Tilton SC, Menachery VD, et al. Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. *J Virol* 2013;87:3885–902. [PubMed: 23365422]
288. Zhou Y, Gong W, Xiao J, et al. Transcriptomic analysis reveals key regulators of mammogenesis and the pregnancy-lactation cycle. *Sci China Life Sci* 2014;57: 340–55. [PubMed: 24554470]
289. Zinser GM, Welsh J. Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. *Mol Endocrinol* 2004;18:2208–23. [PubMed: 15178742]
290. Zinser G, Packman K, Welsh J. Vitamin D(3) receptor ablation alters mammary gland morphogenesis. *Development* 2002;129:3067–76. [PubMed: 12070083]
291. Pellacani D, Bilenky M, Kannan N, et al. Analysis of normal human mammary epigenomes reveals cell-specific active enhancer states and associated transcription factor networks. *Cell Rep* 2016;17:2060–74. [PubMed: 27851968]

292. Suo C, Hrydziusko O, Lee D, et al. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival. *Bioinformatics* 2015;31:2607–13. [PubMed: 25810432]
293. Ciriello G, Gatza ML, Beck AH, et al. Comprehensive molecular portraits of invasive lobular breast cancer. *Cell* 2015;163:506–19. [PubMed: 26451490]
294. Keenan T, Moy B, Mroz EA, et al. Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. *J Clin Oncol* 2015; 33:3621–7. [PubMed: 26371147]
295. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormoneresistant metastatic breast cancer. *Nat Genet* 2013;45:1446–51. [PubMed: 24185510]
296. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature* 2014;507:315–22. [PubMed: 24476821]
297. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61–70. [PubMed: 23000897]
298. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012;487:330–7. [PubMed: 22810696]
299. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015;517:576–82. [PubMed: 25631445]
300. Ahn SM, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. *Hepatology* 2014;60:1972–82. [PubMed: 24798001]
301. Long MD, Thorne JL, Russell J, et al. Cooperative behavior of the nuclear receptor superfamily and its deregulation in prostate cancer. *Carcinogenesis* 2014;35: 262–71. [PubMed: 24104552]
302. Long MD, Campbell MJ. Pan-cancer analyses of the nuclear receptor superfamily. *Nucl Receptor Res* 2015;2 [pii:101182].
303. Satelli A, Rao PS, Thirumala S, et al. Galectin-4 functions as a tumor suppressor of human colorectal cancer. *Int J Cancer* 2011;129:799–809. [PubMed: 21064109]
304. Belo AI, van der Sar AM, Tefsen B, et al. Galectin-4 reduces migration and metastasis formation of pancreatic cancer cells. *PLoS One* 2013;8:e65957. [PubMed: 23824659]
305. Kim SW, Park KC, Jeon SM, et al. Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. *Cell Oncol (Dordr)* 2013;36:169–78. [PubMed: 23378274]
306. Tsai CH, Tzeng SF, Chao TK, et al. Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells. *Cancer Res* 2016;76(19):5756–67. [PubMed: 27485450]
307. Pena C, Garcia JM, Silva J, et al. E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. *Hum Mol Genet* 2005;14:3361–70. [PubMed: 16203744]
308. Pereira F, Barbachano A, Silva J, et al. KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. *Hum Mol Genet* 2011;20:4655–65. [PubMed: 21890490]
309. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res* 2012;22:1790–7. [PubMed: 22955989]
310. Singh P, van den Berg PR, Long MD, et al. Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF- κ B binding that is linked to immune phenotypes. *BMC Genomics* 2017; 18(1):132. [PubMed: 28166722]
311. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. *Eur J Clin Invest* 2005;35:290–304. [PubMed: 15860041]
312. Dougherty U, Mustafi R, Sadiq F, et al. The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer. *Clin Cancer Res* 2014;20:5848–59. [PubMed: 25212605]
313. Giardina C, Madigan JP, Tierney CA, et al. Vitamin D resistance and colon cancer prevention. *Carcinogenesis* 2012;33:475–82. [PubMed: 22180570]

314. Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. *Oncogene* 2009;28:3892–902. [PubMed: 19701245]
315. Liu W, Chen Y, Golan MA, et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. *J Clin Invest* 2013;123:3983–96. [PubMed: 23945234]
316. Long MD, Campbell MJ. Integrative genomic approaches to dissect clinically significant relationships between the VDR cistrome and gene expression in primary colon cancer. *J Steroid Biochem Mol Biol* 2016 [Epub ahead of print].
317. Michalak M, Warnken U, Andre S, et al. Detection of proteome changes in human colon cancer induced by cell surface binding of growth-inhibitory human galectin-4 using quantitative SILAC-based proteomics. *J Proteome Res* 2016; 15(12):4412–22. [PubMed: 27801591]
318. Solmi R, De Sanctis P, Zucchini C, et al. Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR. *Int J Oncol* 2004;25: 1049–56. [PubMed: 15375555]
319. Long MD, van den Berg PR, Russell JL, et al. Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. *Nucleic Acids Res* 2015;43:7330–48. [PubMed: 26117541]

KEY POINTS

- Preclinical and epidemiologic data justify the concept that vitamin D compounds could be exploited as a differentiation therapy for a wide range of malignancies.
- Clinical evaluation of vitamin D compounds has been more equivocal and, although biological responses can be measured in vivo, clinical responses have not justified further evaluation.
- Dissecting mechanisms of cellular resistance is one route to defining patient groups with greater precision who may respond more fully to clinical targeting.
- Large genomic and population datasets are available that can be mined to define patient responses more completely and identify which tumor types may be most effectively targeted.